There is still some way to go before prices hit the $4+ level - still the perceived "breakeven" point for many producers. But low temperatures in the Eastern U.S. are certainly bringing gas back into play. Here are two ways to profit.
Back in early April 2012, in a special report called “The Biotech Buyout Binge,” I explained that we would start seeing a slew of takeovers – engineered by cash-rich biopharmaceutical firms desperate to replace blockbusters that were losing patent protection.
We were right about the so-called “patent cliff.” According to a recent Towers Watson study, there have been about 300 merger-and-acquisition (M&A) deals in the biopharma sector alone.